Role of insulin-like growth factor 1 receptor signalling in cancer
Open Access
- 24 May 2005
- journal article
- review article
- Published by Springer Nature in British Journal of Cancer
- Vol. 92 (12), 2097-2101
- https://doi.org/10.1038/sj.bjc.6602627
Abstract
The insulin-like growth factor (IGF-1) signalling is highly implicated in cancer. In this signalling the IGF-1 receptor (IGF-1R) is unquestionable, the predominating single factor. IGF-1R is crucial for tumour transformation and survival of malignant cell, but is only partially involved in normal cell growth. This is in part due to the interactions with oncogenes. Recent findings suggest a close interplay with the p53/MDM2 pathway. Disturbances in components in the p53/MDM2/IGF-1R network may cause IGF-1R upregulation and growth advantage for the cancer cell. Targeting of IGF-1R is more and more seen as a promising option for future cancer therapy. Single chain antibodies and small molecules with selective effects on IGF-1R dependent malignant growth are of particular interest. Forthcoming clinical trials are welcome and will indeed be the only way to evaluate the impact of IGF-1R targeting in human cancer.Keywords
This publication has 53 references indexed in Scilit:
- P53 and PrognosisCell, 2005
- PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cellsOncogene, 2004
- In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform AOncogene, 2002
- Insulin-like Growth Factor I Induces MDM2-dependent Degradation of p53 via the p38 MAPK Pathway in Response to DNA DamageJournal of Biological Chemistry, 2002
- The contradictions of the insulin-like growth factor 1 receptorOncogene, 2000
- Regulation of the Insulin-Like Growth Factor-I Receptor Gene by Oncogenes and Antioncogenes: Implications in Human CancerMolecular Genetics and Metabolism, 2000
- Circulating concentrations of insulin-like growth factor I and risk of breast cancerThe Lancet, 1998
- Regulation of p53 stability by Mdm2Nature, 1997
- The IGF-I Receptor Gene Promoter Is a Molecular Target for the Ewing's Sarcoma-Wilms' Tumor 1 Fusion ProteinJournal of Biological Chemistry, 1996
- Principles of antibody therapy.BMJ, 1992